Zadik Hazan
Direttore Tecnico/Scientifico/R&S presso Hy BioPharma, Inc.
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Yitzhak Peterburg | M | 73 |
Regenera Pharma Ltd.
 Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | - |
| Michael Steinberg | M | - |
Hy BioPharma, Inc.
 Hy BioPharma, Inc. Medical DistributorsDistribution Services Hy BioPharma, Inc. develops drug technology solutions. The company develops Hypericin for the treatment of cancer, autoimmune disorders, and inflammation. It was established in 2006 and is headquartered in Jamison, PA. | - |
| Sharon Falach-Kovalsky | F | - |
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | - |
| Marius Nacht | M | - |
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | - |
| Shlomo Shalev | M | 62 |
Regenera Pharma Ltd.
Regenera Pharma Ltd. Pharmaceuticals: MajorHealth Technology Regenera Pharma Ltd. develops a novel drug candidate, RPH201 for neurological indications. It also focuses on developing a treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), the most common cause of sudden optic nerve-related vison loss in older people. The company is headquartered in Ness-Ziona, Israel. | - |
| Alfonso Tobia | M | - |
Hy BioPharma, Inc.
Hy BioPharma, Inc. Medical DistributorsDistribution Services Hy BioPharma, Inc. develops drug technology solutions. The company develops Hypericin for the treatment of cancer, autoimmune disorders, and inflammation. It was established in 2006 and is headquartered in Jamison, PA. | - |
| Bernard Cabana | M | - |
Hy BioPharma, Inc.
Hy BioPharma, Inc. Medical DistributorsDistribution Services Hy BioPharma, Inc. develops drug technology solutions. The company develops Hypericin for the treatment of cancer, autoimmune disorders, and inflammation. It was established in 2006 and is headquartered in Jamison, PA. | - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Israele | 4 | 57.14% |
| Stati Uniti | 3 | 42.86% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Zadik Hazan
- Contatti personali
